Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
Barker, Roger A.
Springer International Publishing
MetadataShow full item record
Buttery, P. C., & Barker, R. A. (2020). Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?. Neurotherapeutics, 17 (4), 1539-1562. https://doi.org/10.1007/s13311-020-00940-4
Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder that carries large health and socioeconomic burdens. Current therapies for PD are ultimately inadequate, both in terms of symptom control and in modification of disease progression. Deep brain stimulation and infusion therapies are the current mainstay for treatment of motor complications of advanced disease, but these have very significant drawbacks and offer no element of disease modification. In fact, there are currently no agents that are established to modify the course of the disease in clinical use for PD. Gene and cell therapies for PD are now being trialled in the clinic. These treatments are diverse and may have a range of niches in the management of PD. They hold great promise for improved treatment of symptoms as well as possibly slowing progression of the disease in the right patient group. Here, we review the current state of the art for these therapies and look to future strategies in this fast-moving field.
Review, Gene therapy, lentivirus, adeno-associated virus, growth factor, embryonic, pluripotent
Medical Research Council (G102328, MR/R015724/1)
National Institute for Health Research (146281)
Wellcome Trust (203151/Z/16/Z)
External DOI: https://doi.org/10.1007/s13311-020-00940-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/317024
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/